MindMed



MindMed Recent News

Five Companies Developing Second Generation Psychedelics For Mental Health
MindMed Successfully Completes Phase 1 Trial Of 18-MC
MindMed Shares Update On Phase 2b Trials of LSD For Treating Generalized Anxiety Disorder
EXCLUSIVE: MindMed CEO Rob Barrow On Growth Aspirations, Development Pipeline
How This Company Is Using Psychedelic Medicines and Therapies to Treat Addiction and Mental Illness
Sponsored
EXCLUSIVE: Kevin O'Leary Unpacks Deal Flow, Investments, Perspectives On Disruptive Innovation
Fintech Focus Roundup For June 13, 2021
Fintech Focus For June 11, 2021
EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO
Fintech Focus For May 3, 2021
Fintech Focus Roundup For May 2, 2021
MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of Medicine
Psyched: MindMed and Atai Head For Nasdaq, Psychedelics Search Platforms Grow, Champignon Brands Gets Back To Trading
Psyched: MindMed's 2020 Financials, Psychedelics ETF Rebalancing, Country's First Psychedelics Masters Degree
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
MindMed Reveals Results Of A Study On Personalized MDMA Dosing
Cannabis Countdown: Top 10 Marijuana And Psychedelics Industry News Stories Of The Week
Psyched: The Patents Dilemma, Compass 2020 Earnings, New Psilocybin Bill In NY
Fintech Focus Roundup For February 20, 2020
Cannabis Movers & Shakers: TILT, MindMed, EnWave, Zelira
MindMed To Buy AI Medicine Company HealthMode For CA$42M
Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M
The Horizons Psychedelic Stock Index ETF, As Told By Its Fund Manager